EN DE
Data-driven stock valuation

Zhejiang Shenghua Biok Biology Co Ltd (600226) fair value: what the stock is really worth

We calculate from audited financials what Zhejiang Shenghua Biok Biology Co Ltd is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily, free.

  1. Compare price with fair valuebelow fair value = cheap, above = expensive
  2. Check the quality50 and up solid, 75 and up strong
  3. Watch it or check another stockalert when fair value or trend changes

Industrials · CN · Market cap 17.4B CNY (≈ $2.6B) · ISIN CNE0000010Q7

At a glance

ZS Zhejiang Shenghua Biok Biology Co Ltd 600226 · SHG
Price¥5.84
Fair Value¥0.7565
Upside−87.1%
Quality39/100

Below-average quality, and trading another 672% above our fair value of ¥0.7565.

As of Aug 19, 2026, the fair value of Zhejiang Shenghua Biok Biology Co Ltd is ¥0.7565 per share against a price of ¥5.84, so the fair value sits 87% below the price. A model estimate from reported figures, not an analyst target.

!Mixed Growth (revenue 5y +10.6 %/yr)
!Thin margins · 9.4% net margin
!Low debt · negative free cash flow
!Trails peers (4/12)
!Narrow moat 26/100
!Evidence only low, so the estimate is less certain
!Weak on past: 23 out of 100
!Weak on dividend: 1 out of 100
Evidence: Low Range ¥0.6885 to ¥0.7565

Fair value as of: Aug 19, 2026

From 9 valuation models · updated 19 days ago

Share price −5.3% over the past month.

Watch Zhejiang Shenghua Biok Biology Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • The price sits above even our optimistic bull case (¥0.7565). The favourable scenario is already priced in.
  • Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts.
  • The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
  • The models converge in a tight band (¥0.6885 to ¥0.7565), unusually little disagreement for a valuation.

Price vs Fair Value (5 years)

¥11.41 ¥1.82 Fair Value ¥0.7565 Mar 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 19, 2026.

How to read this chart

60‑month range ¥1.82 – ¥11.41 · fair‑value band ¥0.6885 – ¥0.7565 · the ¥5.84 price screens above the ¥0.7565 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Aug 19, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Zhejiang Shenghua Biok Biology Co Ltd (600226) currently trades at ¥5.84, while our model-based Fair Value estimate is ¥0.7565, implying the stock looks roughly 672.2% overvalued today. The Quality Score stands at 39/100 (below-average quality), in the Industrials sector. Bull case: the Multiples group reads highest at a median of ¥1.08 per share, and 0 of the 9 models we run sit above the ¥5.84 price. Bear case: the Earnings-Based group reads lowest at ¥0.4100, and 9 of the 9 models stay below the price. Evidence for this calculation is low.

Over the trailing twelve months, Zhejiang Shenghua Biok Biology Co Ltd generated revenue of 2.2B CNY at a net margin of 9.4%. Revenue grew 82.2% year over year. It earns a return on equity of 5.6%. The balance sheet holds a net cash position of 248M CNY. Fundamentals as of Aug 19, 2026

Scenario range: ¥0.6885 (bear) to ¥0.7565 (bull), the price of ¥5.84 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target. The share trades about 28% below its 52-week high and 124% above its 52-week low, currently above its 200-day average. For context, the median of 10 Industrials peers we cover trades at 35% fair-value upside, at −87%, 600226 screens richer than that median.

Fair Value models

Based on fiscal year 2024 figures (about 12 months old). Earnings retained since then (¥0.0700 per share) are deliberately not added.

Each model values the company its own way; the fair value above is the evidence-weighted blend. Evidence (0 to 100) shows how complete a model's inputs are. How we calculate →

Note: the current price implies far more future growth than the conservative anchors of our models allow (base growth is deliberately capped, we do not regard such extreme rates as sustainable). Our models are not designed for expectations this high; that is why the individual models scatter extremely (¥0.0700 to ¥1.34). Read the values as a conservative anchor, not as a price target.
Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Owner Earnings ¥0.7100 ¥1.05 ¥1.56 76
Residual Income ¥0.8900 ¥0.9000 ¥0.8900 76
Gordon GGM ¥0.0400 ¥0.0900 ¥0.1400 66
All 9 models by family
DCF Models
Owner Earnings ¥0.7100 ¥1.05 ¥1.56 76
Earnings-Based
Graham-Dodd ¥0.4300 ¥1.34 ¥1.78 65
Lynch FV ¥0.2900 ¥0.4100 ¥0.5400 61
Dividend Discount
Gordon GGM ¥0.0400 ¥0.0900 ¥0.1400 66
DDM Multi-Stage ¥0.0400 ¥0.0700 ¥0.0900 66
Multiples
P/E Multiple ¥0.8100 ¥1.08 ¥1.35 63
P/B Multiple ¥0.8100 ¥1.08 ¥1.35 55
Asset-Based
NCAV (Graham) ¥0.5700 ¥0.7700 ¥1.15 54
Economic Profit
Residual Income ¥0.8900 ¥0.9000 ¥0.8900 76

Widest divergence: Multiples (¥1.08) versus Dividend Discount (¥0.0700). Highest evidence: Owner Earnings (76).

Notify me when 600226 reaches fair value

Put 600226 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 83.4
P/S ratio 11.8 P/E × margin
EPS (TTM) ¥0.0700 price ÷ EPS = P/E 83.4
Dividend yield 0.1% payout 5.0%
Net margin 14.2% FY2024
Return on equity 5.6% TTM
More key figures
Profitability
Return on assets (EBIT) 1.5% avg 5y
Operating margin −1.6% TTM
Growth
Revenue (TTM) 2.2B CNY TTM
Revenue growth (YoY) +82.2% 3y avg +25.1%
Balance sheet & cash flow
Free cash flow −163M CNY FY2024
Net cash 248M CNY FY2024

Figures from reported company fundamentals · as of Aug 19, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 39/100

Of which business quality 41 · Market factors (momentum, volatility) 53

Profitability 30
Margins and returns on capital today
Quality Growth 51
Are margins and returns improving?
Cashflow 4
Earnings quality: real cash, not paper profit
Fin. Strength 88
Balance sheet, leverage, solvency risk
Investment 46
Disciplined investing over empire-building
Low Volatility 39
Calm price path (market factor)
Momentum 54
Price trend over the last 3–12 months (market factor)
52W Momentum 67
Distance to the 52-week high (market factor)
Net Issuance 31
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Zhejiang Hengtong Holding Co.,Ltd. develops, produces, and sells biological pesticides, veterinary drugs, and animal feed additive products in China and Internationally. The company offers electronic and lithium battery copper foil for use in integrated circuit boards, lithium battery electrodes, and other products, as well as amino acid products.

Full company description

Zhejiang Hengtong Holding Co.,Ltd. develops, produces, and sells biological pesticides, veterinary drugs, and animal feed additive products in China and Internationally. The company offers electronic and lithium battery copper foil for use in integrated circuit boards, lithium battery electrodes, and other products, as well as amino acid products. It also engages in the cogeneration of heat and power and central heating, which includes electricity and steam; office and game software development; investment management; and film and television businesses. The company was incorporated in 1999 and is based in Huzhou, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2020 – FY2024 · reported fiscal years

Zhejiang Shenghua Biok Biology Co Ltd reported revenue of 1.3B CNY in FY2024 versus 556M CNY in FY2020, a compound +24.5%/yr. Reported net income was 189M CNY in FY2024.

Growth Quality 42/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2024)
1.3B CNY
Latest YoY
+106.0%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+25.1%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+10.6%
Avg. revenue growth/yr (28Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+13.0%
Value creation/yr (5Y) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year.
+3.8%
Earnings growth per share plus dividend yield: the value created per share and year.
Earnings growth per share+3.7%
Dividend yield0.1%
Trend ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.5Y 3.7% vs 10Y 3.2%, steady
Operating margin (EBIT) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6.1% (2014) → −168.2% (2020) · falling
Worst earnings drop710% (2020) (loss year, drop beyond 100%) · in CNY
⚠ Revenue per share shrinking 15.5%/yr over ~10Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Revenue +24.5%/yr
FY20 556M CNY
FY21 681M CNY
FY22 602M CNY
FY23 648M CNY
FY24 1.3B CNY
Net income
FY20 −942M CNY
FY21 375M CNY
FY22 482M CNY
FY23 166M CNY
FY24 189M CNY
Character of growth · EPS growth decomposed (2013-2024) +7.5 % p.a.
Revenue per share −10.4 %

of which total revenue −4.6 % · buybacks/dilution −6.0 %

EBIT margin +22.3 %
Tax rate −0.9 %
Residual (interest, one-offs) −1.1 %

Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).

600226 screens 672% overvalued. Compare with ITOCHU Corporation →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Zhejiang Shenghua Biok Biology Co Ltd · Fair Value
¥0.7565 −672%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Zhejiang Shenghua Biok Biology Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/600226

Peer Group

Conglomerates · 376 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation
Quality Score 39 · Bottom 25%
Fair Value upside −87% · Bottom 25%
Profitability
Return on equity (TTM) 6% · Above median
Return on assets −1% · Bottom 25%
Net margin (TTM) 9% · Top 25%
Operating margin (TTM) −2% · Bottom 25%
Growth and dividend
Revenue growth 82% · Top 25%
Dividend yield (TTM) 0.1% · Bottom 25%
Balance sheet
Debt / equity 0.09× · Below median

Valuation Multiples vs Conglomerates median · lower = cheaper

P/E (TTM) 83.4× · Priciest 25%
P/B 5.09× · Priciest 25%
P/S (TTM) 8.04× · Priciest 25%

Context: sector, industry, market

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE0 · sector 27
FUTURE100 · sector 17
PAST23 · sector 17
HEALTH95 · sector 89
DIVIDEND1 · sector 41

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Conglomerates stocks, each showing price versus our Fair Value estimate (as of Aug 19, 2026).

Stock Price Fair Value vs Fair Value
ITOCHU Corporation ITOCHU19 7.20 THB 14.40 THB +100%
3M Company MMM $168.56 $76.87 −54%
Honeywell International Inc HON $209.61 $218.95 +4%
CITIC Limited 0267 HK$13.02 HK$26.04 +100%
Poste Italiane S.p.A PST €26.90 €7.65 −72%
Swire Pacific Limited 0019 HK$106.30 HK$36.88 −65%
CK Hutchison Holdings 0001 HK$69.85 HK$100.46 +44%
SK Inc 034730 553,000 KRW 615,077 KRW +11%
PT Astra International Tbk, ASII 4,800 IDR 9,600 IDR +100%
Jardine Matheson Holdings J36 $58.42 $79.11 +35%

Compare Zhejiang Shenghua Biok Biology Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Frequently asked questions

Is Zhejiang Shenghua Biok Biology Co Ltd (600226) overvalued or undervalued?
As of Aug 19, 2026, our model estimates a fair value of ¥0.7565 versus a price of ¥5.84, about −87% upside (overvalued).
What is the fair value of 600226?
Our model-based fair value for Zhejiang Shenghua Biok Biology Co Ltd is ¥0.7565 (as of Aug 19, 2026), built from audited fundamentals. The current price: ¥5.84.
What is the quality score of 600226?
Zhejiang Shenghua Biok Biology Co Ltd has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zhejiang Shenghua Biok Biology Co Ltd (600226)?
Our model-based price target is the fair value of ¥0.7565 (as of Aug 19, 2026) from 9 valuation models. Cautious scenario ¥0.6885, optimistic scenario ¥0.7565. It is a calculation from audited fundamentals, not an analyst target.
What is the Zhejiang Shenghua Biok Biology Co Ltd stock forecast for 2026?
Our models put fair value at ¥0.7565, about −87% upside versus a price of ¥5.84 (overvalued). Cautious scenario ¥0.6885, optimistic scenario ¥0.7565. The calculation is refreshed regularly with new filings.
What is the revenue of Zhejiang Shenghua Biok Biology Co Ltd (600226)?
Zhejiang Shenghua Biok Biology Co Ltd reported trailing-twelve-month revenue of about 2.2B CNY (latest available figure, as of Aug 19, 2026).
What is the net profit margin of 600226?
The net profit margin of Zhejiang Shenghua Biok Biology Co Ltd is about 9.4%, meaning it keeps roughly 9.4% of revenue as net income. Based on the latest reported figures.
Does Zhejiang Shenghua Biok Biology Co Ltd pay a dividend?
Zhejiang Shenghua Biok Biology Co Ltd currently shows a dividend yield of about 0.06% relative to its recent price (as of Aug 19, 2026).
Free · no account needed

Watch Zhejiang Shenghua Biok Biology Co Ltd in the live analysis

One click puts Zhejiang Shenghua Biok Biology Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.